Acuta Capital Partners’s United Therapeutics UTHR Stock Holding History

Acuta Capital Partners’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.32M	Sell	2,224 -72	-3%	-$35.9K	0.93%	21
2025 Q4	$1.12M	Hold	2,296	–	–	0.76%	20
2025 Q3	$963K	Buy	+2,296	New	+$772K	0.99%	22
2023 Q2	–	Sell	-23,500	Closed	-$5.26M	–	42
2023 Q1	$5.26M	Sell	23,500 -9,500	-29%	-$2.34M	3.88%	9
2022 Q4	$9.18M	Buy	33,000 +5,500	+20%	+$1.39M	5.65%	5
2022 Q3	$5.76M	Buy	27,500 +14,500	+112%	+$3.24M	2.48%	15
2022 Q2	$3.06M	Buy	+13,000	New	+$2.64M	1.71%	19
2021 Q4	–	Sell	-3,000	Closed	-$554K	–	52
2021 Q3	$554K	Buy	+3,000	New	+$591K	0.2%	45

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Acuta Capital Partners's UTHR Position: Q1 2026 in Review

Acuta Capital Partners reduced its United Therapeutics (UTHR) stake by 3.1% in Q1 2026, selling an estimated $35.9K and leaving 2,224 shares worth $1.32M. The position accounts for 0.93% of the portfolio, ranked #21.

Acuta Capital Partners first reported a position in UTHR in Q3 2021 and has held it in 8 quarters since. The position peaked at $9.18M in Q4 2022. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

Acuta Capital Partners held 2,224 shares of United Therapeutics worth $1.32M as of Q1 2026.
Acuta Capital Partners sold 72 United Therapeutics shares in Q1 2026, an estimated $35.9K.
United Therapeutics made up 0.93% of Acuta Capital Partners's portfolio in Q1 2026, its #21 holding.
Acuta Capital Partners first reported a position in United Therapeutics in Q3 2021 and has held it in 8 quarters since.
Acuta Capital Partners's United Therapeutics position peaked at $9.18M in Q4 2022.
850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Acuta Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.